Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases

Mohammed Eslam; Aijaz Ahmed; Jean-Pierre Després; Vivekanand Jha; Jason C G Halford; Jack Tan Wei Chieh; David C H Harris; Masaomi Nangaku; Stephen Colagiuri; Giovanni Targher; Shashank Joshi; Christopher D Byrne; Kamlesh Khunti; Mindie H Nguyen; Robert G Gish; Jacob George

doi:10.1016/S2468-1253(21)00132-1

Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases

Lancet Gastroenterol Hepatol. 2021 Sep;6(9):743-753. doi: 10.1016/S2468-1253(21)00132-1. Epub 2021 Jul 12.

Authors

Mohammed Eslam¹, Aijaz Ahmed², Jean-Pierre Després³, Vivekanand Jha⁴, Jason C G Halford⁵, Jack Tan Wei Chieh⁶, David C H Harris⁷, Masaomi Nangaku⁸, Stephen Colagiuri⁹, Giovanni Targher¹⁰, Shashank Joshi¹¹, Christopher D Byrne¹², Kamlesh Khunti¹³, Mindie H Nguyen¹⁴, Robert G Gish¹⁵, Jacob George¹⁶

Affiliations

¹ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia. Electronic address: [email protected].
² Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
³ Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada; Department of Kinesiology, Faculty of Medicine, Université Laval, Québec, QC, Canada; Université Laval, Québec, QC, Canada.
⁴ George Institute for Global Health, UNSW, New Delhi, India; School of Public Health, Imperial College London, London, UK; Manipal Academy of Higher Education, Manipal, India.
⁵ School of Psychology, University of Leeds, Leeds, UK.
⁶ Department of Cardiovascular Medicine, National Heart Centre Singapore, Singapore.
⁷ Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia.
⁸ The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
⁹ Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.
¹⁰ Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
¹¹ Lilavati Hospital and Research Centre, Mumbai, India.
¹² Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Southampton, UK; Nutrition and Metabolism, Faculty of Medicine, University of Southampton, UK.
¹³ Diabetes Research Centre, University of Leicester, Leicester, UK; Leicester General Hospital, Leicester, UK.
¹⁴ Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
¹⁵ Division of Gastroenterology and Hepatology, Loma Linda University, Loma Linda, CA, USA.
¹⁶ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia.

PMID: 34265276
DOI: 10.1016/S2468-1253(21)00132-1

Abstract

With the global epidemics of obesity and associated conditions, including type 2 diabetes, metabolic dysfunction-associated fatty liver disease, chronic kidney disease, hypertension, stroke, cardiovascular disease, osteoporosis, cancer, and cognitive changes, the prevalence of multimorbidity is rapidly increasing worldwide. In this Review, a panel of international experts from across the spectrum of metabolic diseases come together to identify the challenges and provide perspectives on building a framework for a virtual primary care-driven, patient-centred, multidisciplinary model to deliver holistic care for patients with metabolic dysfunction-associated fatty liver disease and associated metabolic diseases. We focus on clinical care and innovative trial design for metabolic dysfunction-associated fatty liver disease and associated metabolic diseases. This work represents a call to action to promote collaboration and partnerships between stakeholders for improving the lives of people with, or at risk of, metabolic dysfunction-associated fatty liver disease and associated metabolic diseases.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Clinical Trials as Topic / methods*
Global Health
Humans
Metabolic Diseases / complications*
Metabolic Diseases / epidemiology
Metabolic Diseases / therapy
Non-alcoholic Fatty Liver Disease / complications
Non-alcoholic Fatty Liver Disease / epidemiology
Non-alcoholic Fatty Liver Disease / therapy*
Prevalence
Risk Factors